What's The Big-Up-Front Deal? Biopharma Up-Fronts Hit A High
Executive Summary
Biopharma companies paid an average of $82 million up front when in-licensing assets over the past three years, but in some cases they shelled out much more. The number of deals with big up-fronts has doubled since 2013, and 2015 is on track to exceed last year's value.
You may also be interested in...
Infectious Disease Companies Catch More Investors
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
Investors Boost Metabolic Companies
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
Mega Medtech M&A Momentum In 2015
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.